Lancet Oncology corrects 10-year IMPORT LOW outcome details
A published correction has revised several outcome statements from the 10-year report of UK IMPORT LOW, the multicentre, open-label, randomised phase 3 non-inferiority trial of partial-breast radiotherapy after breast conservation surgery for women with early breast cancer. The correction touches both table 1 and multiple sentences in the Results section, tightening the record around long-term event rates and the distribution of second malignancies across treatment groups.
The amended text matters because this trial has served as one of the key long-term references for how local breast irradiation can be tailored after surgery without sacrificing disease control. Even small numerical corrections in a 10-year dataset can alter how clinicians interpret absolute risk, especially when the endpoints include contralateral primaries, non-breast second cancers, and composite breast cancer events.
Revised long-term event counts across treatment groups
The most visible change appears in the row for Any breast cancer event within the intention-to-treat population in table 1. The corrected Results section now states that 63 participants developed contralateral breast primary cancers. These events were distributed as 24 in the whole-breast group, 20 in the reduced-dose group, and 19 in the partial-breast group. Of these contralateral cancers, 53 were invasive.
A single line in a mature radiotherapy trial can carry substantial clinical weight. Contralateral primaries do not reflect local field control in the same direct way as in-breast recurrence, yet they remain central to survivorship counseling because they represent new disease in the untreated breast and influence the interpretation of long-term breast event burden.
The correction also revises the tally for non-breast second primary cancers. These were reported in 159 patients, with 62 cases in the whole-breast group and 57 in the reduced-dose group, alongside the corresponding figure for the partial-breast group in the amended text. In a long follow-up oncology study, second primaries often become a major part of the safety narrative, especially when competing risks from aging, prior treatment exposure, and background cancer incidence begin to accumulate over a decade.
Angiosarcoma and composite breast cancer events
The correction further amends the sentence describing rare but clinically important breast angiosarcomas. Three breast angiosarcomas were reported. Even without further numerical expansion in the correction notice, that event remains important because angiosarcoma is one of the most feared late complications in breast radiotherapy, largely because of its rarity, aggressive biology, and the difficulty of distinguishing sporadic from treatment-associated cases without careful adjudication.
In parallel, the composite burden of breast events has been restated. Breast cancer-related events of any kind were reported for 170 patients. The corrected sentence also specifies a 10-year breast cancer-free interval of 91.8% with a 95% confidence interval of 89.3–93.7 in the reduced-dose group. For clinicians, that estimate is the kind of long-horizon metric that frames the practical question after breast conservation surgery: how much recurrence protection is preserved when the radiation field or dose is reduced?
Local therapy in early breast cancer is always a balance between intensifying control and limiting collateral injury to normal tissue. The logic behind partial-breast or reduced-dose approaches is biological as much as technical: by restricting treatment to the region at highest residual risk, radiation exposure to uninvolved breast tissue, heart, lung, and skin can be reduced while still addressing the operative bed where recurrence is most likely to emerge. Long-term data are essential because the benefit profile is not fully visible in the first few years after treatment.
Why the correction matters for interpretation
This correction does not introduce a new trial conclusion or alter the overall design of the study. It does, however, restore accuracy to the event counts that shape the 10-year risk narrative. In breast radiotherapy, where non-inferiority is often judged across narrow margins and small absolute differences, corrected event accounting is not a clerical detail. It is part of the clinical evidence base.
For oncologists and breast specialists, the amended numbers help refine three distinct questions. First, how often did contralateral breast cancers appear over a decade of follow-up? Second, what was the total burden of second primary malignancies outside the breast? Third, how durable was disease control when summarized as a breast cancer-free interval in the reduced-dose cohort?
The corrected data also remind readers that composite endpoints in oncology can include several biologically different outcomes under one umbrella. Contralateral primaries, in-field recurrences, second non-breast cancers, and rare vascular malignancies do not share a single mechanism, yet each contributes to the long-term safety profile of a breast radiotherapy strategy. In practical terms, a therapy can look stable on one endpoint while shifting risk into another domain that only becomes visible with extended surveillance.
What the amended record preserves from the original trial message
Even with the corrected wording, the core structure of the 10-year report remains intact: this was a multicentre, open-label, randomised, controlled, phase 3, non-inferiority trial evaluating partial-breast radiotherapy after breast conservation surgery in women with early breast cancer. The correction updates the bookkeeping around outcomes rather than rewriting the trial architecture.
That distinction is especially relevant in radiotherapy studies, where long follow-up can reveal rare late events that are easy to undercount or misclassify in preliminary reporting. A corrected table or sentence may appear minor on the page, yet it can materially affect how readers quote event frequencies, compare arms, or counsel patients about long-term expectations after surgery and adjuvant radiation.
The amended results now give a cleaner numerical frame for the 10-year safety and efficacy story of IMPORT LOW. For clinicians, the practical value lies in having the long-term event counts aligned with the published record before those figures are carried into guidelines, reviews, or patient discussions about breast-conserving treatment and radiation field selection.